schliessen

Filtern

 

Bibliotheken

Placebo-Controlled Comparison of Captopril, Metoprolol, and Hydrochlorothiazide Therapy in Non - Insulin-Dependent Diabetic Patients With Primary Hypertension

The antihypertensive effect of captopril, metoprolol, and hydrochlorothiazide was compared in 23 non-insulin-dependent (NIDDM) diabetic patients ≤ 75 years of age, with borderline to moderate primary hypertension. In a double blind, placebo-controlled cross-over trial the patients were treated with... Full description

Journal Title: American journal of hypertension 1992, Vol.5 (5-Pt-1), p.257-265
Main Author: Gall, Mari-Anne
Other Authors: Rossing, Peter , Skøtt, Peter , Rommel, Eva , Mathiesen, Elisabeth R. , Gerdes, Lars U. , Lauritzen, Mogens , Vølund, Aage , Fœrgeman, Ole , Beck-Nielsen, Henning , Pawing, Hans-Henrik
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: New York, NY: Oxford University Press
ID: ISSN: 0895-7061
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_crossref_primary_10_1093_ajh_5_5_257
title: Placebo-Controlled Comparison of Captopril, Metoprolol, and Hydrochlorothiazide Therapy in Non - Insulin-Dependent Diabetic Patients With Primary Hypertension
format: Article
creator:
  • Gall, Mari-Anne
  • Rossing, Peter
  • Skøtt, Peter
  • Rommel, Eva
  • Mathiesen, Elisabeth R.
  • Gerdes, Lars U.
  • Lauritzen, Mogens
  • Vølund, Aage
  • Fœrgeman, Ole
  • Beck-Nielsen, Henning
  • Pawing, Hans-Henrik
subjects:
  • Aged
  • Antihypertensive agents
  • antihypertensive therapy
  • Biological and medical sciences
  • Captopril - therapeutic use
  • Cardiovascular system
  • Diabetes Mellitus, Type 2 - diet therapy
  • Diabetes Mellitus, Type 2 - drug therapy
  • Diabetes Mellitus, Type 2 - physiopathology
  • Double-Blind Method
  • Female
  • Glomerular Filtration Rate - drug effects
  • Humans
  • Hydrochlorothiazide - adverse effects
  • Hydrochlorothiazide - therapeutic use
  • Hypertension - drug therapy
  • Hypertension - physiopathology
  • Hypoglycemic Agents - antagonists & inhibitors
  • kidney function
  • Lipids - blood
  • Male
  • Medical sciences
  • metabolic control
  • Metoprolol - therapeutic use
  • Middle Aged
  • Non-insulin-dependent diabetes mel-litus
  • Pharmacology. Drug treatments
  • primary hypertension
ispartof: American journal of hypertension, 1992, Vol.5 (5-Pt-1), p.257-265
description: The antihypertensive effect of captopril, metoprolol, and hydrochlorothiazide was compared in 23 non-insulin-dependent (NIDDM) diabetic patients ≤ 75 years of age, with borderline to moderate primary hypertension. In a double blind, placebo-controlled cross-over trial the patients were treated with 25 to 50 mg captopril, 50 to 100 mg metoprolol, 12.5 to 25 mg hydrochlorothiazide, and placebo, each given twice daily for 8 weeks. Anti-diabetic treatment remained unchanged during the study. After receiving placebo for a 4 week run-in period, arterial blood pressure was 168/101 ± 93/10 (mean ± SEM) mm Hg. Diastolic blood pressure was lowered significantly during all active treatment periods compared to the placebo value of 97 ± 2 mm Hg: captopril, 92 ± 1 mm Hg; metoprolol, 90 ± 1 mm Hg; hydrochlorothiazide, 91 ± 1 mm Hg. Metabolic variables were not significantly altered by captopril and metoprolol, while hydrochlorothiazide treatment increased hemoglobin Alc from 7.5 ± 0.3 to 8.2 ± 0.4% (P < .001), decreased high-density lipoprotein-cholesterol from 1.19 ± 0.08 to 1.10 ± 0.06 mmol/L (P < .05). Glomerular filtration rate, urinary albumin excretion, orthostatic blood pressure response, and digital systolic blood pressure in the lower limb remained unchanged during the active treatment periods. The frequency of subjective adverse effects was acceptable during active treatment and not significantly different compared to placebo. We conclude that antihypertensive treatment for 8 weeks with captopril or metoprolol in NIDDM patients is well-tolerated and causes no deterioration in metabolic control and kidney function, while hydrochlorothiazide causes a slight deterioration in glycemic control and lipid profile. Am J Hypertens 1992;5:257-265.
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0895-7061
fulltext: fulltext
issn:
  • 0895-7061
  • 1879-1905
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK1.619747
LOCALfalse
PrimoNMBib
record
control
sourceidistex_cross
recordidTN_cdi_crossref_primary_10_1093_ajh_5_5_257
sourceformatXML
sourcesystemPC
sourcerecordidark_67375_HXZ_VQ50L0HR_J
originalsourceidFETCH-LOGICAL-1423t-8f84c45f0df6440234549ce463fffee921b852e7f065121e80858cfd8af8dd023
addsrcrecordideNp1kU9v1DAQxS0EKkvhxBnJB240WzuJE-eIUsoWbWFB5Y-4RF57rLh47ch2JZYPw2fF21RFQkI-zMjz_J71G4SeU7KkpKtOxfV4ypZsWbL2AVpQ3nYF7Qh7iBaEd6xoSUMfoycxXhNC6qahR-iIMk4JLRfo98YKCVtf9N6l4K0FhXu_m0Qw0TvsNe7FlPwUjD3Bl3DovPW5F07h1V4FL0frg0-jEb-MAnw1QhDTHhuH32eDAl-4eGONK85gAqfAJXxmxBaSkXgjkskXEX81acSbYHYi7LPrBCGBi8a7p-iRFjbCs7t6jD6fv7nqV8X6w9uL_vW6oHVZpYJrXsuaaaJ0U9ekrGpWdxLqptJaA3Ql3XJWQqtJw2hJgRPOuNSKC82Vyvpj9Gr2lcHHGEAP0_ybgZLhAHnIkAeWT4ac1S9m9XSz3YH6q52p5vnLu7mIUlgdhJMm3suqjlX0NpT-EypNykgOmxDG_ie6mN-YmODnvaUIP4amrVo2rL59H758ZGRNVp-Gd9UfuqenpQ
sourcetypeAggregation Database
isCDItrue
recordtypearticle
display
typearticle
titlePlacebo-Controlled Comparison of Captopril, Metoprolol, and Hydrochlorothiazide Therapy in Non - Insulin-Dependent Diabetic Patients With Primary Hypertension
sourceAlma/SFX Local Collection
creatorGall, Mari-Anne ; Rossing, Peter ; Skøtt, Peter ; Rommel, Eva ; Mathiesen, Elisabeth R. ; Gerdes, Lars U. ; Lauritzen, Mogens ; Vølund, Aage ; Fœrgeman, Ole ; Beck-Nielsen, Henning ; Pawing, Hans-Henrik
creatorcontribGall, Mari-Anne ; Rossing, Peter ; Skøtt, Peter ; Rommel, Eva ; Mathiesen, Elisabeth R. ; Gerdes, Lars U. ; Lauritzen, Mogens ; Vølund, Aage ; Fœrgeman, Ole ; Beck-Nielsen, Henning ; Pawing, Hans-Henrik
descriptionThe antihypertensive effect of captopril, metoprolol, and hydrochlorothiazide was compared in 23 non-insulin-dependent (NIDDM) diabetic patients ≤ 75 years of age, with borderline to moderate primary hypertension. In a double blind, placebo-controlled cross-over trial the patients were treated with 25 to 50 mg captopril, 50 to 100 mg metoprolol, 12.5 to 25 mg hydrochlorothiazide, and placebo, each given twice daily for 8 weeks. Anti-diabetic treatment remained unchanged during the study. After receiving placebo for a 4 week run-in period, arterial blood pressure was 168/101 ± 93/10 (mean ± SEM) mm Hg. Diastolic blood pressure was lowered significantly during all active treatment periods compared to the placebo value of 97 ± 2 mm Hg: captopril, 92 ± 1 mm Hg; metoprolol, 90 ± 1 mm Hg; hydrochlorothiazide, 91 ± 1 mm Hg. Metabolic variables were not significantly altered by captopril and metoprolol, while hydrochlorothiazide treatment increased hemoglobin Alc from 7.5 ± 0.3 to 8.2 ± 0.4% (P < .001), decreased high-density lipoprotein-cholesterol from 1.19 ± 0.08 to 1.10 ± 0.06 mmol/L (P < .05). Glomerular filtration rate, urinary albumin excretion, orthostatic blood pressure response, and digital systolic blood pressure in the lower limb remained unchanged during the active treatment periods. The frequency of subjective adverse effects was acceptable during active treatment and not significantly different compared to placebo. We conclude that antihypertensive treatment for 8 weeks with captopril or metoprolol in NIDDM patients is well-tolerated and causes no deterioration in metabolic control and kidney function, while hydrochlorothiazide causes a slight deterioration in glycemic control and lipid profile. Am J Hypertens 1992;5:257-265.
identifier
0ISSN: 0895-7061
1EISSN: 1879-1905
2DOI: 10.1093/ajh/5.5.257
3PMID: 1581012
languageeng
publisherNew York, NY: Oxford University Press
subjectAged ; Antihypertensive agents ; antihypertensive therapy ; Biological and medical sciences ; Captopril - therapeutic use ; Cardiovascular system ; Diabetes Mellitus, Type 2 - diet therapy ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - physiopathology ; Double-Blind Method ; Female ; Glomerular Filtration Rate - drug effects ; Humans ; Hydrochlorothiazide - adverse effects ; Hydrochlorothiazide - therapeutic use ; Hypertension - drug therapy ; Hypertension - physiopathology ; Hypoglycemic Agents - antagonists & inhibitors ; kidney function ; Lipids - blood ; Male ; Medical sciences ; metabolic control ; Metoprolol - therapeutic use ; Middle Aged ; Non-insulin-dependent diabetes mel-litus ; Pharmacology. Drug treatments ; primary hypertension
ispartofAmerican journal of hypertension, 1992, Vol.5 (5-Pt-1), p.257-265
rights1994 INIST-CNRS
lds50peer_reviewed
citedbyFETCH-LOGICAL-1423t-8f84c45f0df6440234549ce463fffee921b852e7f065121e80858cfd8af8dd023
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3953102$$DView record in Pascal Francis
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1581012$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Gall, Mari-Anne
1Rossing, Peter
2Skøtt, Peter
3Rommel, Eva
4Mathiesen, Elisabeth R.
5Gerdes, Lars U.
6Lauritzen, Mogens
7Vølund, Aage
8Fœrgeman, Ole
9Beck-Nielsen, Henning
10Pawing, Hans-Henrik
title
0Placebo-Controlled Comparison of Captopril, Metoprolol, and Hydrochlorothiazide Therapy in Non - Insulin-Dependent Diabetic Patients With Primary Hypertension
1American journal of hypertension
addtitleAJH
descriptionThe antihypertensive effect of captopril, metoprolol, and hydrochlorothiazide was compared in 23 non-insulin-dependent (NIDDM) diabetic patients ≤ 75 years of age, with borderline to moderate primary hypertension. In a double blind, placebo-controlled cross-over trial the patients were treated with 25 to 50 mg captopril, 50 to 100 mg metoprolol, 12.5 to 25 mg hydrochlorothiazide, and placebo, each given twice daily for 8 weeks. Anti-diabetic treatment remained unchanged during the study. After receiving placebo for a 4 week run-in period, arterial blood pressure was 168/101 ± 93/10 (mean ± SEM) mm Hg. Diastolic blood pressure was lowered significantly during all active treatment periods compared to the placebo value of 97 ± 2 mm Hg: captopril, 92 ± 1 mm Hg; metoprolol, 90 ± 1 mm Hg; hydrochlorothiazide, 91 ± 1 mm Hg. Metabolic variables were not significantly altered by captopril and metoprolol, while hydrochlorothiazide treatment increased hemoglobin Alc from 7.5 ± 0.3 to 8.2 ± 0.4% (P < .001), decreased high-density lipoprotein-cholesterol from 1.19 ± 0.08 to 1.10 ± 0.06 mmol/L (P < .05). Glomerular filtration rate, urinary albumin excretion, orthostatic blood pressure response, and digital systolic blood pressure in the lower limb remained unchanged during the active treatment periods. The frequency of subjective adverse effects was acceptable during active treatment and not significantly different compared to placebo. We conclude that antihypertensive treatment for 8 weeks with captopril or metoprolol in NIDDM patients is well-tolerated and causes no deterioration in metabolic control and kidney function, while hydrochlorothiazide causes a slight deterioration in glycemic control and lipid profile. Am J Hypertens 1992;5:257-265.
subject
0Aged
1Antihypertensive agents
2antihypertensive therapy
3Biological and medical sciences
4Captopril - therapeutic use
5Cardiovascular system
6Diabetes Mellitus, Type 2 - diet therapy
7Diabetes Mellitus, Type 2 - drug therapy
8Diabetes Mellitus, Type 2 - physiopathology
9Double-Blind Method
10Female
11Glomerular Filtration Rate - drug effects
12Humans
13Hydrochlorothiazide - adverse effects
14Hydrochlorothiazide - therapeutic use
15Hypertension - drug therapy
16Hypertension - physiopathology
17Hypoglycemic Agents - antagonists & inhibitors
18kidney function
19Lipids - blood
20Male
21Medical sciences
22metabolic control
23Metoprolol - therapeutic use
24Middle Aged
25Non-insulin-dependent diabetes mel-litus
26Pharmacology. Drug treatments
27primary hypertension
issn
00895-7061
11879-1905
fulltexttrue
rsrctypearticle
creationdate1992
recordtypearticle
recordideNp1kU9v1DAQxS0EKkvhxBnJB240WzuJE-eIUsoWbWFB5Y-4RF57rLh47ch2JZYPw2fF21RFQkI-zMjz_J71G4SeU7KkpKtOxfV4ypZsWbL2AVpQ3nYF7Qh7iBaEd6xoSUMfoycxXhNC6qahR-iIMk4JLRfo98YKCVtf9N6l4K0FhXu_m0Qw0TvsNe7FlPwUjD3Bl3DovPW5F07h1V4FL0frg0-jEb-MAnw1QhDTHhuH32eDAl-4eGONK85gAqfAJXxmxBaSkXgjkskXEX81acSbYHYi7LPrBCGBi8a7p-iRFjbCs7t6jD6fv7nqV8X6w9uL_vW6oHVZpYJrXsuaaaJ0U9ekrGpWdxLqptJaA3Ql3XJWQqtJw2hJgRPOuNSKC82Vyvpj9Gr2lcHHGEAP0_ybgZLhAHnIkAeWT4ac1S9m9XSz3YH6q52p5vnLu7mIUlgdhJMm3suqjlX0NpT-EypNykgOmxDG_ie6mN-YmODnvaUIP4amrVo2rL59H758ZGRNVp-Gd9UfuqenpQ
startdate199205
enddate199205
creator
0Gall, Mari-Anne
1Rossing, Peter
2Skøtt, Peter
3Rommel, Eva
4Mathiesen, Elisabeth R.
5Gerdes, Lars U.
6Lauritzen, Mogens
7Vølund, Aage
8Fœrgeman, Ole
9Beck-Nielsen, Henning
10Pawing, Hans-Henrik
general
0Oxford University Press
1Elsevier Science
scope
0BSCLL
1IQODW
2CGR
3CUY
4CVF
5ECM
6EIF
7NPM
8AAYXX
9CITATION
sort
creationdate199205
titlePlacebo-Controlled Comparison of Captopril, Metoprolol, and Hydrochlorothiazide Therapy in Non - Insulin-Dependent Diabetic Patients With Primary Hypertension
authorGall, Mari-Anne ; Rossing, Peter ; Skøtt, Peter ; Rommel, Eva ; Mathiesen, Elisabeth R. ; Gerdes, Lars U. ; Lauritzen, Mogens ; Vølund, Aage ; Fœrgeman, Ole ; Beck-Nielsen, Henning ; Pawing, Hans-Henrik
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1423t-8f84c45f0df6440234549ce463fffee921b852e7f065121e80858cfd8af8dd023
rsrctypearticles
prefilterarticles
languageeng
creationdate1992
topic
0Aged
1Antihypertensive agents
2antihypertensive therapy
3Biological and medical sciences
4Captopril - therapeutic use
5Cardiovascular system
6Diabetes Mellitus, Type 2 - diet therapy
7Diabetes Mellitus, Type 2 - drug therapy
8Diabetes Mellitus, Type 2 - physiopathology
9Double-Blind Method
10Female
11Glomerular Filtration Rate - drug effects
12Humans
13Hydrochlorothiazide - adverse effects
14Hydrochlorothiazide - therapeutic use
15Hypertension - drug therapy
16Hypertension - physiopathology
17Hypoglycemic Agents - antagonists & inhibitors
18kidney function
19Lipids - blood
20Male
21Medical sciences
22metabolic control
23Metoprolol - therapeutic use
24Middle Aged
25Non-insulin-dependent diabetes mel-litus
26Pharmacology. Drug treatments
27primary hypertension
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Gall, Mari-Anne
1Rossing, Peter
2Skøtt, Peter
3Rommel, Eva
4Mathiesen, Elisabeth R.
5Gerdes, Lars U.
6Lauritzen, Mogens
7Vølund, Aage
8Fœrgeman, Ole
9Beck-Nielsen, Henning
10Pawing, Hans-Henrik
collection
0Istex
1Pascal-Francis
2Medline
3MEDLINE
4MEDLINE (Ovid)
5MEDLINE
6MEDLINE
7PubMed
8CrossRef
jtitleAmerican journal of hypertension
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Gall, Mari-Anne
1Rossing, Peter
2Skøtt, Peter
3Rommel, Eva
4Mathiesen, Elisabeth R.
5Gerdes, Lars U.
6Lauritzen, Mogens
7Vølund, Aage
8Fœrgeman, Ole
9Beck-Nielsen, Henning
10Pawing, Hans-Henrik
formatjournal
genrearticle
ristypeJOUR
atitlePlacebo-Controlled Comparison of Captopril, Metoprolol, and Hydrochlorothiazide Therapy in Non - Insulin-Dependent Diabetic Patients With Primary Hypertension
jtitleAmerican journal of hypertension
addtitleAJH
date1992-05
risdate1992
volume5
issue5-Pt-1
spage257
epage265
pages257-265
issn0895-7061
eissn1879-1905
notes
0The study was supported by grants from Squibb Novo. All tablets and matching placebos were provided by Squibb UK.
1Address correspondence and reprint requests to Mari-Anne Gall, MD, Steno Memorial and Hvidöre Hospital, Emiliekildevej 1, DK-2930, Klampenborg, Denmark.
abstractThe antihypertensive effect of captopril, metoprolol, and hydrochlorothiazide was compared in 23 non-insulin-dependent (NIDDM) diabetic patients ≤ 75 years of age, with borderline to moderate primary hypertension. In a double blind, placebo-controlled cross-over trial the patients were treated with 25 to 50 mg captopril, 50 to 100 mg metoprolol, 12.5 to 25 mg hydrochlorothiazide, and placebo, each given twice daily for 8 weeks. Anti-diabetic treatment remained unchanged during the study. After receiving placebo for a 4 week run-in period, arterial blood pressure was 168/101 ± 93/10 (mean ± SEM) mm Hg. Diastolic blood pressure was lowered significantly during all active treatment periods compared to the placebo value of 97 ± 2 mm Hg: captopril, 92 ± 1 mm Hg; metoprolol, 90 ± 1 mm Hg; hydrochlorothiazide, 91 ± 1 mm Hg. Metabolic variables were not significantly altered by captopril and metoprolol, while hydrochlorothiazide treatment increased hemoglobin Alc from 7.5 ± 0.3 to 8.2 ± 0.4% (P < .001), decreased high-density lipoprotein-cholesterol from 1.19 ± 0.08 to 1.10 ± 0.06 mmol/L (P < .05). Glomerular filtration rate, urinary albumin excretion, orthostatic blood pressure response, and digital systolic blood pressure in the lower limb remained unchanged during the active treatment periods. The frequency of subjective adverse effects was acceptable during active treatment and not significantly different compared to placebo. We conclude that antihypertensive treatment for 8 weeks with captopril or metoprolol in NIDDM patients is well-tolerated and causes no deterioration in metabolic control and kidney function, while hydrochlorothiazide causes a slight deterioration in glycemic control and lipid profile. Am J Hypertens 1992;5:257-265.
copNew York, NY
pubOxford University Press
pmid1581012
doi10.1093/ajh/5.5.257